Capital Gazette wins special Pulitzer Prize citation for coverage of newsroom shooting that killed five

Shares rise for biotech company on hopes for drug


Shares of Human Genome Sciences Inc. jumped nearly 8 percent yesterday after the Rockville biotechnology company buttressed a better-than-expected financial report with upbeat insights into one of its more promising drug candidates.

Human Genome shares jumped 99 cents, or 7.7 percent, to close at $13.85 yesterday on the Nasdaq stock market. Slightly more than 3 million shares traded, almost double the daily average for the past six months of just over 1.6 million shares.

For its fourth quarter, which ended Dec. 31, Human Genome reported a net loss of $48.9 million, or 38 cents per share, smaller than the net loss of $59.8 million, or 46 cents per share, during the comparable quarter in 2002, the company said.

Analysts had expected Human Genome to lose 41 cents per share in the fourth quarter, according to a survey of 14 analysts conducted by Zacks Investment Research.

A one-time license fee from Pfizer Inc. recorded in the fourth quarter boosted revenue for the final three months of last year to $4.6 million. That was almost eight times the $600,000 in revenue reported for the corresponding period in 2002, Human Genome said.

For all of last year, Human Genome reported a loss of $185.3 million, or $1.44 per share. That compared with a net loss of $219.7 million, or $1.71 per share, in 2002.

Revenue last year totaled $8.2 million, up from $3.6 million in 2002, the company said.

Positive news involving LymphoStat-B, a drug for treating rheumatoid arthritis and the most serious form of lupus ignited investor interest yesterday, said Christopher J. Raymond, an analyst who follows Human Genome for Robert W. Baird & Co.

"For this company, it's the project that's probably got the largest potential of all their early-stage [drug] candidates," Raymond said.

Because it's an early-stage drug, however, it's difficult to predict success or failure.

This month, for instance, Human Genome ended development of Repifermin, a drug to treat mouth sores in chemotherapy patients. It was once viewed as a primary product candidate for the company. Clinical trials found that Repifermin was not significantly more effective than a placebo in treating the painful condition.

Human Genome said it's at work on several LymphoStat-B clinical trials. Investors can expect data soon that will serve as a progress report of sorts on the drug, Raymond said. "That's what got [investors] excited," he said.

Copyright © 2019, The Baltimore Sun, a Baltimore Sun Media Group publication | Place an Ad